The serum-based VeriStrat® test is associated with proinflammatory reactants and clinical outcome in non-small cell lung cancer patients

被引：0
|
作者：
Mary Jo Fidler
Cristina L. Fhied
Joanna Roder
Sanjib Basu
Selina Sayidine
Ibtihaj Fughhi
Mark Pool
Marta Batus
Philip Bonomi
Jeffrey A. Borgia
机构：
[1] Sections of Medical Oncology at Rush University Medical Center,Departments of Pathology and Cell & Molecular Medicine
[2] Pathology,undefined
[3] Rush University Medical Center,undefined
[4] Biodesix,undefined
[5] Inc,undefined
[6] Preventative Medicine,undefined
[7] Rush University Medical Center,undefined
[8] Cell and Molecular Medicine at Rush University Medical Center,undefined
[9] Rush University Medical Center,undefined
来源：
BMC Cancer | / 18卷
关键词：
Biomarker; Serum; Non-small cell lung cancer (NSCLC); Erlotinib; Luminex; VeriStrat;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [31] The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer
    Li, Ning
    Shao, Kang
    Chen, Zhaoli
    Qiu, Bin
    Wang, Zhen
    Tan, Fengwei
    Wang, Jiwen
    Tan, Xiaogang
    Li, Baozhong
    Xiong, Meihua
    Zhou, Fang
    He, Jie
    FAMILIAL CANCER, 2011, 10 (02) : 331 - 336
  • [32] The impact of positive cancer family history on the clinical features and outcome of patients with non-small cell lung cancer
    Ning Li
    Kang Shao
    Zhaoli Chen
    Bin Qiu
    Zhen Wang
    Fengwei Tan
    Jiwen Wang
    Xiaogang Tan
    Baozhong Li
    Meihua Xiong
    Fang Zhou
    Jie He
    Familial Cancer, 2011, 10 : 331 - 336
  • [33] Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer
    Tas, F
    Duranyildiz, D
    Argon, A
    Oguz, H
    Camlica, H
    Yasasever, V
    Topuz, E
    MEDICAL ONCOLOGY, 2005, 22 (04) : 353 - 358
  • [34] Serum levels of leptin and proinflammatory cytokinesin advanced stage non-small cell lung cancer.
    Topuz, E
    Tas, F
    Argon, A
    Yildiz, DD
    Oguz, H
    Yasasever, V
    Eralp, Y
    Aydiner, A
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 189S - 189S
  • [35] Serum levels of leptin and proinflammatory cytokines in advanced-stage non-small cell lung cancer
    Faruk Tas
    Derya Duranyildiz
    Andac Argon
    Hilal Oğuz
    Hakan Camlica
    Vildan Yasasever
    Erkan Topuz
    Medical Oncology, 2005, 22 : 353 - 358
  • [36] The clinical significance of autophagy in patients with non-small cell lung cancer
    Nakashima, Nariyasu
    Liu, Dage
    Nakano, Takayuki
    Go, Tetsuhiko
    Yokomise, Hiroyasu
    CANCER SCIENCE, 2018, 109 : 1425 - 1425
  • [37] Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab: Methodological Issues
    Safiri, Saeid
    Ashrafi-Asgarabad, Ahad
    JOURNAL OF THORACIC ONCOLOGY, 2018, 13 (05) : E85 - E86
  • [38] Decreased Expression of miR-125a-3p is Associated with the Clinical Outcome of Non-Small Cell Lung Cancer Patients
    Wu, Chunyan
    Hou, Likun
    JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S983 - S984
  • [39] Cancer-associated fibroblast phenotypes are associated with patient outcome in non-small cell lung cancer
    Cords, Lena
    Engler, Stefanie
    Haberecker, Martina
    Ruschoff, Jan Hendrik
    Moch, Holger
    de Souza, Natalie
    Bodenmiller, Bernd
    CANCER CELL, 2024, 42 (03) : 396 - 412.e5
  • [40] Clinical outcome of early development of pneumonitis in non-small cell lung cancer patients treated with durvalumab
    Sugimoto, Akira
    Zenke, Yoshitaka
    Hojo, Hidehiro
    Nakamura, Masaki
    Udagawa, Hibiki
    Kirita, Keisuke
    Ikeda, Takaya
    Matsumoto, Singo
    Yoh, Kiyotaka
    Niho, Seiji
    Akimoto, Tetsuo
    Goto, Koichi
    ANNALS OF ONCOLOGY, 2019, 30
12345